Diane A. Lane

Diane A. Lane

Auto-generated profile, based on publicly available information

Diane A. Lane

Washington State University Vancouver, 14204 Northeast Salmon Creek Avenue, Vancouver, WA 98686, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GFGiuseppe Faraco
Giuseppe Faraco
YSYukio Sugiyama
Yukio Sugiyama
DLDiane Lane
Diane Lane
LGLidia Garcia-Bonilla
Lidia Garcia-Bonilla
HCHaejoo Chang
Haejoo Chang
CICostantino Iadecola
Costantino Iadecola
Hypertension is a leading risk factor for dementia, but the mechanisms underlying its damaging effects on the brain are poorly understood. Due to a lack of energy reserves, the brain relies on continuous delivery of blood flow to its active regions in accordance with their dynamic metabolic needs. Hypertension disrupts these vital regulatory mechanisms, leading to the neuronal dysfunction and damage underlying cognitive impairment. Elucidating the cellular bases of these impairments is essential for developing new therapies. Perivascular macrophages (PVMs) represent a distinct population of resident brain macrophages that serves key homeostatic roles but also has the potential to generate large amounts of reactive oxygen species (ROS). Here, we report that PVMs are critical in driving the alterations in neurovascular regulation and attendant cognitive impairment in mouse models of hypertension. This effect was mediated by an increase in blood-brain barrier permeability that allowed angiotensin II to enter the perivascular space and activate angiotensin type 1 receptors in PVMs, leading to production of ROS through the superoxide-producing enzyme NOX2. These findings unveil a pathogenic role of PVMs in the neurovascular and cognitive dysfunction associated with hypertension and identify these cells as a putative therapeutic target for diseases associated with cerebrovascular oxidative stress.

22 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YXYing Xue Xie
Ying Xue Xie
NNNima N. Naseri
Nima N. Naseri
JFJasmine Fels
Jasmine Fels
PKParinati Kharel
Parinati Kharel
YNYoonmi Na
Yoonmi Na
MSManu Sharma
Manu Sharma
Considerable evidence supports the release of pathogenic aggregates of the neuronal protein α-Synuclein (αSyn) into the extracellular space. While this release is proposed to instigate the neuron-to-neuron transmission and spread of αSyn pathology in synucleinopathies including Parkinson’s disease, the molecular-cellular mechanism(s) remain unclear. To study this, we generated a new mouse model to specifically immunoisolate neuronal lysosomes, and established a long-term culture model where αSyn aggregates are produced within neurons without the addition of exogenous fibrils. We show that neuronally generated pathogenic species of αSyn accumulate within neuronal lysosomes in mouse brains and primary neurons. We then find that neurons release these pathogenic αSyn species via SNARE-dependent lysosomal exocytosis. The released aggregates are non-membrane enveloped and seeding-competent. Additionally, we find that this release is dependent on neuronal activity and cytosolic Ca2+. These results propose lysosomal exocytosis as a central mechanism for the release of aggregated and degradation-resistant proteins from neurons.

11 December 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KJKatherine Jackman
Katherine Jackman
TKTimo Kahles
Timo Kahles
DLDiane Lane
Diane Lane
LGLidia Garcia-Bonilla
Lidia Garcia-Bonilla
TATakato Abe
Takato Abe
CICostantino Iadecola
Costantino Iadecola
Loss-of-function mutations of progranulin (PGRN) have been linked to frontotemporal dementia, but little is known about the effects of PGRN deficiency on the brain in health and disease. PGRN has been implicated in neurovascular development, inflammation, and Wnt signaling, a pathway involved in the formation of the blood–brain barrier (BBB). Because BBB alterations and inflammation contribute to ischemic brain injury, we examined the role of PGRN in the brain damage produced by ischemia-reperfusion.PGRN+/−andPGRN−/−mice underwent middle cerebral artery occlusion (MCAO) with monitoring of cerebral blood flow. Infarct volume and motor deficits were assessed 72 h later. Post-ischemic inflammation was examined by expression of inflammatory genes and flow cytometry. BBB structure and permeability were examined by electron microscopy (EM) and Evans blue (EB) extravasation, respectively. MCAO resulted in ∼60% larger infarcts inPGRN+/−andPGRN−/−mice, an effect independent of hemodynamic factors or post-ischemic inflammation. Rather, massive hemorrhages and post-ischemic BBB disruption were observed, unrelated to degradation of tight junction (TJ) proteins or matrix metalloproteinases (MMPs). By EM, TJ were 30–52% shorter, fewer, and less interlocking, suggesting a weaker seal between endothelial cells. Intracerebral injection of platelet-derived growth factor-CC (PDGF-CC), which increases BBB permeability, resulted in a more severe BBB breakdown inPGRN+/−andPGRN−/−than wild-type mice. We describe a previously unrecognized involvement of PGRN in the expression of key ultrastructural features of the BBB. Such a novel vasoprotective role of PGRN may contribute to brain dysfunction and damage in conditions associated with reduced PGRN function.

1 July 1997 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
PHP. Homayoun
P. Homayoun
ETE. B. Rodriguez de Turco
E. B. Rodriguez de Turco
NPN. E. Parkins
N. E. Parkins
DLD. C. Lane
D. C. Lane
JSJ. Soblosky
J. Soblosky
NBN. G. Bazan
N. G. Bazan
Lipid second messengers such as arachidonic acid and its metabolites and diacylglycerols (DAGs) are affected in brain injury. Therefore, changes in the pool size and the fatty acid composition of free fatty acids (FFAs) and DAGs were analyzed in different rat brain areas 4 and 35 days after traumatic injury. Cortical impact injury of low‐grade severity was applied in the right frontal somatosensory cortex. Four days after injury, FFAs and DAGs were increased by three‐ and twofold, respectively, in the injured cortex and to a lesser extent in the contralateral cortex compared with sham‐operated animals. Docosahexaenoic acid followed by stearic acid, and arachidonic acid, displayed the greatest changes in both FFAs and DAGs. By day 35, free stearic, oleic, and arachidonic acids remained elevated in the damaged cortex (1.5‐fold each). DAGs showed the greatest change, reaching values 2.7‐fold higher than sham in all frontal and occipital cortical areas, including brainstem. Oleoyl‐ and arachidonoyl‐DAGs (four‐ and threefold increase, respectively) followed by docosahexaenoyl‐DAGs (twofold) contributed to the DAG accumulation. These results reveal that traumatic brain injury triggers a sustained and time‐dependent activation of phospholipase‐mediated signaling pathways leading to membrane phospholipid degradation and targeting, early on, docosahexaenoyl phospholipid‐enriched excitable membranes.

1 January 2005 in Neuroscience
Verified
Journal Article
Closed access
DLD.A. Lane
D.A. Lane
PPP.A. Patel
P.A. Patel
MMM.M. Morgan
M.M. Morgan

26 June 2018 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LGLidia Garcia-Bonilla
Lidia Garcia-Bonilla
DBDavid Brea
David Brea
CBCorinne Benakis
Corinne Benakis
DLDiane A. Lane
Diane A. Lane
MMMichelle Murphy
Michelle Murphy
JAJosef Anrather
Josef Anrather
Exposure to low-dose lipopolysaccharide (LPS) before cerebral ischemia is neuroprotective in stroke models, a phenomenon termed preconditioning (PC). Although it is well established that LPS-PC induces central and peripheral immune responses, the cellular mechanisms modulating ischemic injury remain unclear. Here, we investigated the role of immune cells in the brain protection afforded by PC and tested whether monocytes may be reprogrammed by ex vivo LPS exposure, thus modulating inflammatory injury after cerebral ischemia in male mice. We found that systemic injection of low-dose LPS induces a Ly6Chi monocyte response that protects the brain after transient middle cerebral artery occlusion (MCAO) in mice. Remarkably, adoptive transfer of monocytes isolated from preconditioned mice into naive mice 7 h after transient MCAO reduced brain injury. Gene expression and functional studies showed that IL-10, inducible nitric oxide synthase, and CCR2 in monocytes are essential for neuroprotection. This protective activity was elicited even if mouse or human monocytes were exposed ex vivo to LPS and then injected into male mice after stroke. Cell-tracking studies showed that protective monocytes are mobilized from the spleen and reach the brain and meninges, where they suppress postischemic inflammation and neutrophil influx into the brain parenchyma. Our findings unveil a previously unrecognized subpopulation of splenic monocytes capable of protecting the brain with an extended therapeutic window and provide the rationale for cell therapies based on the delivery of autologous or allogeneic protective monocytes in patients after ischemic stroke. SIGNIFICANCE STATEMENT Inflammation is a key component of the pathophysiology of the brain in stroke, a leading cause of death and disability with limited therapeutic options. Here, we investigate endogenous mechanisms of protection against cerebral ischemia. Using lipopolysaccharide (LPS) preconditioning (PC) as an approach to induce ischemic tolerance in mice, we found generation of neuroprotective monocytes within the spleen, from which they traffic to the brain and meninges, suppressing postischemic inflammation. Importantly, systemic LPS-PC can be mimicked by adoptive transfer of in vitro-preconditioned mouse or human monocytes at translational relevant time points after stroke. This model of neuroprotection may facilitate clinical efforts to increase the efficacy of BM mononuclear cell treatments in acute neurological diseases such as cerebral ischemia.